Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "RMAT"

1412 News Found

Eli Lilly appoints Dr. Vivek Jha as Senior Director – Commercial Strategy, AI & Transformation
People | September 03, 2025

Eli Lilly appoints Dr. Vivek Jha as Senior Director – Commercial Strategy, AI & Transformation

He will be leading the design and execution of transformative strategies that harness the power of AI and automation, drive process optimization, and ignite digital innovation


ICN to organize virtual discussion on
R&D | June 02, 2025

ICN to organize virtual discussion on "Digital Transformation: The Catalyst for Agile and Smarter Process" on June 4

Speakers for the session are: Dr. Richard Lobo, Global Head Business Excellence, Innovation, R&D and Chief Ethics Counsellor, Tata Chemicals; Dr. Debabrata Rautaray, Vice President and Chief Product Development & Innovation Officer, DCM Shriram Chemicals Innovation Centre; Dr. Prashant Puri, Head - R&D, Deepak Fertilizers and Petrochemicals Corporation (DFPCL); Dr. Deepak S Panmand, General Manager (R&D), Dhanuka Agritech; Dr. Mudassir. K. Munshi, Team Leader, Deepak Nitrite; and Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals


GMM Pfaudler Group appoints Gregory Gelhaus as Chief Transformation Officer
People | May 06, 2025

GMM Pfaudler Group appoints Gregory Gelhaus as Chief Transformation Officer

Gelhaus has a proven track record of driving business growth


JP Nadda inaugurates new Library and Informatics Centre at LGB Regional Institute of Mental Health
News | January 09, 2025

JP Nadda inaugurates new Library and Informatics Centre at LGB Regional Institute of Mental Health

He also laid the foundation stone for a state-of-the-art 50-bedded Critical Care Block (CCB)


FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy
Drug Approval | December 07, 2024

FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy

Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients


Emcure Pharma forms subsidiary to strengthen dermatology portfolio
News | November 04, 2024

Emcure Pharma forms subsidiary to strengthen dermatology portfolio

The newly setup entity, Emcutix Biopharmaceuticals Limited, plans to significantly expand Emcure’s offerings


Sun Pharma presents clinical efficacy and safety data in severe dermatological conditions at 2024 EADV Congress
News | September 27, 2024

Sun Pharma presents clinical efficacy and safety data in severe dermatological conditions at 2024 EADV Congress

The company will also share results in two additional posters for deuruxolitinib


Biocon Biologics announces new dermatology data to be presented at EADV Congress 2024
Biotech | September 25, 2024

Biocon Biologics announces new dermatology data to be presented at EADV Congress 2024

These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity